Bluebird Bio’s Killer T-Cells Have “Impressive” Results Against Myeloma – Forbes
Forbes |
Bluebird Bio's Killer T–Cells Have "Impressive" Results Against Myeloma
Forbes based Bluebird Bio and Summit, N.J.-based Celgene, is a form of CAR-T, short for chimeric antigen receptor T–cell, for the type of white blood cell and the modifications made to it. This CAR-T targets a protein found in multiple myeloma cells called B … Cellular Therapies for Multiple Myeloma: A Paradigm Shift Bluebird Bio CAR–T delays multiple myeloma progression by one year, but is that enough? #ASCO18: Bluebird & Celgene's CAR–T nears 1 year of PFS in multiple myeloma |
